naphthalimides has been researched along with Myelodysplastic Syndromes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feldman, EJ | 1 |
1 other study(ies) available for naphthalimides and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Topics: Adenine; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Cytarabine; Cytogenetics; Female; Germany; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Naphthalimides; Naphthyridines; Organophosphonates; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Thiazoles | 2011 |